Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas’ Vaprisol Approved For “Water Poisoning” Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Arginine vasopressin antagonist is the first drug indicated for the treatment of euvolemic hyponatremia.

You may also be interested in...



Cornerstone’s Hyponatremia Therapy Lixivaptan Will Get Advisory Panel Scrutiny

The hyponatremia drug is a selective vasopressin V2-receptor antagonist, like Astellas’ Vaprisol and Otsuka’s Samsca.

Astellas' Vaprisol Receives Second Indication

FDA has approved Astellas Pharma's Vaprisol (conivaptan) for the intravenous treatment of hospitalized patients with hypervolemic hyponatremia, the Japanese company announced March 2

Astellas’ Vaprisol Receives Second Indication

Vasopressin antagonist clears FDA for treatment of hospitalized patients with hypervolemic hyponatremia.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel